Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-mCD3-MDNA132
- Development stage
- Preclinical
- Lead developer
- Medicenna Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Anti-mCD3-MDNA132 is a preclinical, first-in-class IL-13 directed Cell Engager (ICE) developed by Medicenna Therapeutics. It is a bispecific fusion protein consisting of MDNA132, an IL-13 Superkine, fused to an anti-CD3 antibody. The molecule is designed to target the IL-13 decoy receptor (IL-13Rα2), which is overexpressed in various solid tumors, and simultaneously bind to CD3 on T cells to recruit and activate them within the tumor microenvironment. This approach is part of Medicenna's BiSKITs™ (Bifunctional SuperKine ImmunoTherapies) program, which aims to enhance the ability of Superkines to treat immunologically 'cold' tumors by converting them into 'hot' tumors, thereby improving the efficacy of cancer immunotherapy.
- Other names
- IL-13 directed Cell EngagerIL13 directed Cell EngagerIL 13 directed Cell EngagerICEMDNA132-anti-CD3MDNA-132-anti-CD3MDNA 132-anti-CD3
02
Targets
CD3 (T-cell surface glycoprotein CD3)IL13RA2 (Interleukin-13 receptor subunit alpha 2)
Beyond the preview
Go deeper on Anti-mCD3-MDNA132.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anti-mCD3-MDNA132.